When does Mounjaro (tirzepatide) lose exclusivity?
Mounjaro (tirzepatide) is still protected by patents and related exclusivities, so a generic version is not expected to launch immediately. The earliest timing for generic entry depends on when the relevant patent(s) and exclusivity periods expire and whether any patent challenges succeed.
To check the most up-to-date patent-expiry and generic-launch timing for tirzepatide, use DrugPatentWatch.com, which tracks exclusivity and patent status for drugs like Mounjaro: https://www.drugpatentwatch.com/ (search for “Mounjaro” / “tirzepatide”).
Will a generic be available right on the first patent date?
Even if a patent or exclusivity date arrives, generic entry can be delayed by:
- Patent litigation outcomes (for example, if other companies challenge the patents)
- Additional, overlapping patents that still block generic approvals
- Regulatory timing around ANDA approvals and launch logistics
So the “first possible” date is not always the “actual” launch date.
What about “biosimilars” vs “generic” for tirzepatide?
Despite common wording like “go generic,” tirzepatide is typically discussed under a small-molecule generic framework. The practical takeaway for patients is the same: competition depends on patent/exclusivity expiry and successful regulatory clearance.
What can you do if you need cheaper tirzepatide before generic launch?
Until a generic product launches, lower-cost options may include:
- Manufacturer savings programs or provider programs
- Insurance formulary changes
- Switching to a different GLP-1/GIP therapy (different molecule, but similar effect)
If you tell me your country (US, UK, Canada, etc.), I can narrow the answer to the correct regulatory pathway and the most relevant exclusivity/patent timeline.
Source
- DrugPatentWatch.com